Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.